🇺🇸 FDA
Patent

US 11453719

Compositions and methods for treating cancer with anti-ROR1 immunotherapy

granted A61KA61K38/1774A61P

Quick answer

US patent 11453719 (Compositions and methods for treating cancer with anti-ROR1 immunotherapy) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Sep 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K38/1774, A61P, A61P35/00